Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 15, Issue 11, Pages 1553-1566
Publisher
Informa Healthcare
Online
2015-09-11
DOI
10.1517/14712598.2015.1071348
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).
- (2017) M. G. Kris et al. JOURNAL OF CLINICAL ONCOLOGY
- High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer
- (2015) E. Pailler et al. ANNALS OF ONCOLOGY
- Translational Implications of Tumor Heterogeneity
- (2015) M. Jamal-Hanjani et al. CLINICAL CANCER RESEARCH
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Immunohistochemical Analysis in the Evaluation of EML4-ALK Gene Rearrangement in Lung Cancer
- (2015) Harold C. Sullivan et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
- (2014) H. A. Yu et al. ANNALS OF ONCOLOGY
- Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboringBRAFmutations in the Lung Cancer Mutation Consortium
- (2014) Liza C. Villaruz et al. CANCER
- Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non-Small Cell Lung Cancer: A Meta-analysis
- (2014) M. Qiu et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
- (2014) Christian Rolfo et al. CANCER TREATMENT REVIEWS
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
- (2014) G. R. Oxnard et al. CLINICAL CANCER RESEARCH
- The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
- (2014) C. Costa et al. CLINICAL CANCER RESEARCH
- Circulating Tumor DNA as a Liquid Biopsy for Cancer
- (2014) E. Heitzer et al. CLINICAL CHEMISTRY
- The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
- (2014) Francesco Passiglia et al. CURRENT DRUG TARGETS
- Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy
- (2014) Mihaly Cserepes et al. EUROPEAN JOURNAL OF CANCER
- Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection
- (2014) Jae Hyun Jeon et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
- (2014) Christian Rolfo et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Reply to A. Soultati et al
- (2014) David Robert Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project
- (2014) Fiona H. Blackhall et al. JOURNAL OF CLINICAL ONCOLOGY
- Liquid Biopsies: Genotyping Circulating Tumor DNA
- (2014) Luis A. Diaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients
- (2014) Wei Li et al. LUNG CANCER
- Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma
- (2014) Min Hwan Kim et al. LUNG CANCER
- Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
- (2014) J.L. Kuiper et al. LUNG CANCER
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures
- (2014) Baoping Guo et al. PLoS One
- BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
- (2014) Dong Chen et al. PLoS One
- MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis
- (2014) Anastasios Dimou et al. PLoS One
- Prognostic Value of Epidermal Growth Factor Receptor Mutations in Resected Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis
- (2014) Zhixuan Zhang et al. PLoS One
- Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
- (2014) Yaxiong Zhang et al. PLoS One
- Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
- (2014) Zhijie Wang et al. PLoS One
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- ROS1-Rearranged Lung Cancer
- (2013) Akihiko Yoshida et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations
- (2013) T. Kinno et al. ANNALS OF ONCOLOGY
- Molecular Pathways: ROS1 Fusion Proteins in Cancer
- (2013) K. D. Davies et al. CLINICAL CANCER RESEARCH
- Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer
- (2013) S. Cardarella et al. CLINICAL CANCER RESEARCH
- Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non–Small-Cell Lung Cancer Segregated According to KRAS Mutation Status
- (2013) Giulio Metro et al. Clinical Lung Cancer
- Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
- (2013) Giuseppe Bronte et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immunohistochemical Profiling of ALK Fusion Gene–Positive Adenocarcinomas of the Lung
- (2013) Yasuhiro Sakai et al. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
- Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK-Positive Non–Small-Cell Lung Cancer
- (2013) Emma Pailler et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Somatic Genomic Alterations in Circulating Tumors Cells: Another Step Forward in Non–Small-Cell Lung Cancer?
- (2013) Daniel B. Costa JOURNAL OF CLINICAL ONCOLOGY
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of the Prognostic and Predictive Effects ofKRASMutation Status andKRASMutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- (2013) Frances A. Shepherd et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- High T790M Detection Rate in TKI-Naive NSCLC with EGFR Sensitive Mutation: Truth or Artifact?
- (2013) Xin Ye et al. Journal of Thoracic Oncology
- Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib
- (2013) C. Santelmo et al. LUNG CANCER
- Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis
- (2013) Daquan Meng et al. LUNG CANCER
- Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors
- (2013) Jong-Mu Sun et al. LUNG CANCER
- Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas
- (2013) Wei-shuai Liu et al. MEDICAL ONCOLOGY
- Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization
- (2013) Christina I Selinger et al. MODERN PATHOLOGY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
- (2013) Pablo Martinez et al. PLoS One
- Prognostic Significance of Circulating Tumor Cells in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis
- (2013) Jianwei Huang et al. PLoS One
- Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
- (2012) K. D. Davies et al. CLINICAL CANCER RESEARCH
- The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies
- (2012) Lidia Rita Corsini et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
- (2012) Ji-Youn Han et al. JOURNAL OF CLINICAL ONCOLOGY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
- (2012) Kang-Yi Su et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib
- (2012) Sandra P. D’Angelo et al. Journal of Thoracic Oncology
- Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation
- (2012) Yoshihiko Fujita et al. Journal of Thoracic Oncology
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
- (2012) Giulio Metro et al. LUNG CANCER
- Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
- (2012) J. De Grève et al. LUNG CANCER
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
- (2011) R. Rosell et al. CLINICAL CANCER RESEARCH
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
- (2011) Antonio Marchetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations
- (2011) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
- (2011) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
- (2011) Matthew G. Krebs et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH
- (2011) Eunhee S. Yi et al. Journal of Thoracic Oncology
- Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains
- (2011) Chenguang Li et al. Journal of Thoracic Oncology
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma
- (2010) Giuseppe Bronte et al. CANCER TREATMENT REVIEWS
- Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
- (2010) Geoffrey R. Oxnard et al. CLINICAL CANCER RESEARCH
- The biology and treatment of EML4-ALK non-small cell lung cancer
- (2010) Takaaki Sasaki et al. EUROPEAN JOURNAL OF CANCER
- Involvement of Grb2 Adaptor Protein in Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK)-mediated Signaling and Anaplastic Large Cell Lymphoma Growth
- (2010) Ludovica Riera et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
- (2010) Patrick J. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
- (2010) Yihua Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-BAC Component but not Epidermal Growth Factor Receptor Gene Mutation is Associated with Poor Outcomes in Small Adenocarcinoma of the Lung
- (2010) Naruyuki Kobayashi et al. Journal of Thoracic Oncology
- EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
- (2010) Kenichi Suda et al. Journal of Thoracic Oncology
- Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma
- (2010) Takayuki Kosaka et al. Journal of Thoracic Oncology
- The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data
- (2010) Lingxiang Liu et al. Journal of Thoracic Oncology
- Proteomics Analysis of Bladder Cancer Exosomes
- (2010) Joanne L. Welton et al. MOLECULAR & CELLULAR PROTEOMICS
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
- (2009) K. Schmid et al. CLINICAL CANCER RESEARCH
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- (2009) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma
- (2009) Young Joo Lee et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
- (2009) Chen Mao et al. LUNG CANCER
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer
- (2008) Jaime Acquaviva et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
- (2008) G. J. Riely et al. CLINICAL CANCER RESEARCH
- Expression and mutational analysis ofMETin human solid cancers
- (2008) Patrick C. Ma et al. GENES CHROMOSOMES & CANCER
- Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
- (2008) Chang-Qi Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Association Between Estrogen Receptor-β Expression and Epidermal Growth Factor Receptor Mutation in the Postoperative Prognosis of Adenocarcinoma of the Lung
- (2008) Naohiro Nose et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma
- (2008) Jenifer L. Marks et al. Journal of Thoracic Oncology
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- The cancer biomarker problem
- (2008) Charles L. Sawyers NATURE
- Detection of Mutations inEGFRin Circulating Lung-Cancer Cells
- (2008) Shyamala Maheswaran et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now